Dongkoo Bio&Pharma will continue to develop
innovative products and meet criteria of the best quality
Introduction
to the
Research
Center
R&D Center conducts research not only on incrementally modified drugs but also on diverse business area such as first generic, stem cell medical device, bio medicine, cosmeceutical product, etc.
Research
Center
Strategies
- Secure mid/long-term future growth engines by developing new promising projects
- Strengthen CMO business by providing products combined competitiveness and efficiency
- Focus R&D on developing differentiated products/technologies based on the platform technology
- Establish Quality by Design system for efficient and advanced research
Research
Areas
-
Development of products
to improve the quality of life- Development of urologic disease medicines
- Development of skin disease medicines
- Development of geriatric medicines such as diabetes, hypertension, coxalgia respiratory system disease, etc
-
Development of
new drugs- NCE discovery through Open Innovation
- Application and development of stem cells
- Drug Repositioning
-
Development of
incrementally modified drugs- Development of new salt and stereoisomeric drugs
- Development of the first introduced medicines in Korea whose safety and efficacy tests are exempted after Phase 1
- Development of drugs that meet criteria of the preferential marketing license
-
Development of
differentiated medicines- Development of controlled release formulations
- Development of formulation for enhanced bioavailability
- Development of formulation with better efficacy and fewer adverse effect